Donofrio Gaetano, Sartori Chiara, Ravanetti Lara, Cavirani Sandro, Gillet Laurent, Vanderplasschen Alain, Taddei Simone, Flammini Cesidio Filippo
Università di Parma, Facoltà di Medicina Veterinaria, Dipartimento di Salute Animale, Sezione di Malattie Infettive degli Animali, via del Taglio 8, 43100 Parma, Italy.
BMC Biotechnol. 2007 Oct 18;7:68. doi: 10.1186/1472-6750-7-68.
The biological characteristics of BoHV-4 make it a good candidate as a gene delivery vector for vaccination purposes. These characteristics include little or no pathogenicity, unlikely oncogenicity, the capability to accommodate large amounts of foreign genetic material, the ability to infect several cell types from different animal species, and the ability to maintain transgene expression in both undifferentiated and differentiated cells.
A recombinant bovine herpesvirus 4 (BoHV-4CMV-IgKE2-14 Delta TK) expressing an enhanced secreted form of the bovine viral diarrhea virus (BVDV) structural glycoprotein E2 (gE2-14), obtained by the removal of the putative transmembrane domain and addition of a 14 amino acids peptide at its carboxyl terminal and an immunoglobulin K signal peptide to the amino terminal, was successfully constructed using a Recombineering (recombination -mediated genetic engineering) approach on BoHV-4 cloned as bacterial artificial chromosome. The galactokinase - based recombineering system was modified by the introduction of a kanamycin expression cassette and a kanamycin selection step that allowed a significant reduction of the untargeted background clones. BoHV-4CMV-IgKE2-14 Delta TK infected cell lines highly expressed gE2-14, which maintained native antigenic properties in a serum neutralization inhibition test. When rabbits and sheep were immunized with BoHV-4CMV-IgKE2-14 Delta TK, high levels of serum neutralized antibodies against BVDV were generated.
This work highlights the engineerization of BoHV-4 genome as a vector for vaccine purposes and may provide the basis for BVDV vaccination exploiting the BoHV-4- based vector that delivers an improved secreted version of the BVDV structural glycoprotein E2.
牛疱疹病毒4型(BoHV-4)的生物学特性使其成为用于疫苗接种目的的基因传递载体的理想候选者。这些特性包括几乎没有致病性或无致病性、不太可能致癌、能够容纳大量外源遗传物质、能够感染来自不同动物物种的多种细胞类型,以及能够在未分化和分化细胞中维持转基因表达。
通过去除假定的跨膜结构域并在其羧基末端添加一个14个氨基酸的肽段以及在氨基末端添加一个免疫球蛋白K信号肽,获得了一种表达牛病毒性腹泻病毒(BVDV)结构糖蛋白E2增强分泌形式(gE2-14)的重组牛疱疹病毒4型(BoHV-4CMV-IgKE2-14 Delta TK)。使用重组工程(重组介导的基因工程)方法,在作为细菌人工染色体克隆的BoHV-4上成功构建了该病毒。通过引入卡那霉素表达盒和卡那霉素选择步骤,对基于半乳糖激酶的重组工程系统进行了改进,这使得非靶向背景克隆显著减少。BoHV-4CMV-IgKE2-14 Delta TK感染的细胞系高度表达gE2-14,其在血清中和抑制试验中保持天然抗原特性。当用BoHV-4CMV-IgKE2-14 Delta TK免疫兔子和绵羊时,产生了高水平的抗BVDV血清中和抗体。
这项工作突出了将BoHV-4基因组工程化作为疫苗载体的应用,并可能为利用基于BoHV-4的载体进行BVDV疫苗接种提供基础,该载体可传递改良的分泌型BVDV结构糖蛋白E2。